SynthesisSaudi medical journal2026
Understanding the Cost Consequences of Pharmacist Roles in Managing Long-Term Illnesses: A Systematic Review.
Synthesis in Saudi medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This review looked at how different pharmacist-led services influence medication spending and other economic outcomes for people living with long-term illnesses. Methods: To gather the evidence, we followed the PRISMA 2020 approach and a comprehensive search was conducted using multiple sources, including Web of Science, ProQuest, Scopus, the Directory of Open Access Journals, ScienceDirect, PubMed, and Google Scholar. We included studies that examined pharmacist involvement in medication management such as MTM, medication reconciliation, deprescribing efforts, or full medication reviews and that reported some form of cost or economic outcome in chronic disease care. We left out non-English work, conference abstracts, case reports, and papers without accessible full text. After screening all records, 1420 studies met the inclusion criteria. These ranged from randomized trials to cohort studies, pre-post designs, and a few economic modeling analyses. We evaluated methodological quality using the MMAT (2018), and for the modeling work, we applied the Drummond checklist. Results: Across the different study types, pharmacist involvement generally led to fewer medication-related problems, better adherence, and more appropriate medication use. Several studies showed that these changes translated into lower overall costs for example, through fewer adverse drug events, fewer hospital visits, or by switching patients to more affordable but clinically appropriate therapy options. Some economic evaluations even suggested that these interventions saved more money than they cost. Programs that combined medication review with patient education, deprescribing, and follow-up tended to show the clearest benefits. Conclusion: Taken together, the findings indicate that involving pharmacists more directly in the medication management of individuals with chronic conditions leads to better clinical results and more favorable economic outcomes. These findings support the idea of involving pharmacists more closely within chronic-care teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.